Foghorn Therapeutics (FHTX) Current Leases (2019 - 2026)

Foghorn Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Current Leases fell 79.56% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 79.56% YoY), while the FY2025 annual figure was $923000.0, down 89.82% from the prior year.
• Current Leases was $1.9 million for Q1 2026 at Foghorn Therapeutics, up from $923000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $9.1 million in Q1 2025 to a low of $923000.0 in Q4 2025.
• Historically, Current Leases has averaged $6.8 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Current Leases soared 42.68% in 2023, then slumped 89.82% in 2025.
• A 5-year view of Current Leases shows it stood at $6.0 million in 2022, then soared by 42.68% to $8.5 million in 2023, then grew by 6.45% to $9.1 million in 2024, then plunged by 89.82% to $923000.0 in 2025, then jumped by 101.84% to $1.9 million in 2026.
• The last three Current Leases figures came in at $1.9 million (Q1 2026), $923000.0 (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.